Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6316)
All Articles published online
|
Publishing Process of This Article
|
May 14, 2019 (publication date) through May 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239 [PMID: 31143073 DOI: 10.3748/wjg.v25.i18.2229] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm |
| Number | Citing Articles |
| 1 |
Sergii V. Fedorchenko, Tatiana Martynovych, Zhanna Klimenko, Iryna Solianyk. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors. Journal of Medical Virology 2021; 93(8): 4975 doi: 10.1002/jmv.26935
|
| 2 |
Sumaiah J. Alarfaj, Abdullah Alzahrani, Anfal Alotaibi, Malak Almutairi, Mashael Hakami, Njood Alhomaid, Noori Alharthi, Ghazwa B. Korayem, Abdullah Alghamdi. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia. Saudi Pharmaceutical Journal 2022; 30(10): 1448 doi: 10.1016/j.jsps.2022.07.005
|
| 3 |
Mirinda Ann Gormley, Matthew J Akiyama, Lior Rennert, Kerry A Howard, Brianna L Norton, Irene Pericot-Valverde, Sam Muench, Moonseong Heo, Alain H Litwin. Changes in Health-related Quality of Life for Hepatitis C Virus–Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response. Clinical Infectious Diseases 2022; 74(9): 1586 doi: 10.1093/cid/ciab669
|
| 4 |
N. Jeelan Basha, S. M. Basavarajaiah, K. Shyamsunder. Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Molecular Diversity 2022; 26(5): 2915 doi: 10.1007/s11030-022-10387-8
|
| 5 |
Ahmet Sahin, Ozlem Akay. Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey. Annals of Saudi Medicine 2023; 43(5): 308 doi: 10.5144/0256-4947.2023.308
|
| 6 |
V. T. Ivashkin, V. P. Chulanov, N. A. Mamonova, M. V. Maevskaya, M. S. Zharkova, I. N. Tikhonov, P. O. Bogomolov, E. V. Volchkova, A. S. Dmitriev, O. O. Znojko, E. A. Klimova, K. V. Kozlov, I. E. Kravchenko, E. Yu. Malinnikova, R. V. Maslennikov, M. I. Mikhailov, K. E. Novak, I. G. Nikitin, V. E. Syutkin, E. V. Esaulenko, A. A. Sheptulin, E. N. Shirokova, N. D. Yushchuk. Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2023; 33(1): 84 doi: 10.22416/1382-4376-2023-33-1-84-124
|
| 7 |
Bernd Schulte, Christiane S Schmidt, Jakob Manthey, Lisa Strada, Stefan Christensen, Konrad Cimander, Herbert Görne, Pavel Khaykin, Norbert Scherbaum, Stefan Walcher, Stefan Mauss, Ingo Schäfer, Uwe Verthein, Jürgen Rehm, Jens Reimer. Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study. Open Forum Infectious Diseases 2020; 7(8) doi: 10.1093/ofid/ofaa317
|